Literature DB >> 21248470

Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack.

Hanying Bao1, Peilin Lu, Yi Li, Lijuan Wang, Haiyan Li, Donghua He, Yang Yang, Yi Zhao, Li Yang, Micheal Wang, Qing Yi, Zhen Cai.   

Abstract

Multiple myeloma (MM) is an incurable B-cell malignancy characterized by accumulation of malignant plasma cells in the bone marrow and by recurrent or persistent infections. Toll-like receptors (TLRs) are essential in the host defense against infections. The aim of this study was to investigate TLR initiated responses in MM cells including proliferation, anti-apoptosis and immune escape. Myeloma cell lines gene transcription, cell cycle and protein expression were detected by RT-PCR, real-time PCR, western blot, ELISA and flow cytometry analysis. 3H-thymidine was used for measuring cell proliferation, and Annexin V-PI flow cytometry for the detection of cell apoptosis. We show that human myeloma cell lines expressed TLRs,and LPS induced the proliferation and partially protected MM.1S and ARP-1 cells from adriamycin-induced apoptosis. LPS appears to induce proliferation via MyD88 and MAPKs signaling. In addition, LPS treatment upregulated myeloma cell secretion of cytokine IL-18 and expression of immunoregulatory factors B7-H1, B7-H2 and CD40 mRNA and helped myeloma cells to escape immune surveillance. Our results show that TLRs are functional on myeloma tumor cells, and the ligands to these TLRs have a functional role in affecting myeloma cell proliferation, survival, and response to chemotherapy and immune attacks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248470     DOI: 10.4161/cbt.11.1.13878

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

1.  Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88.

Authors:  Adetutu T Egunsola; Carolyn L Zawislak; Afua A Akuffo; Samantha A Chalmers; Jason C Ewer; Caroline M Vail; Jeffrey C Lombardo; Dana N Perez; Robert A Kurt
Journal:  Cell Immunol       Date:  2011-10-25       Impact factor: 4.868

2.  Effects of β-catenin on differentially expressed genes in multiple myeloma.

Authors:  Hui Chen; Wei Chai; Bin Li; Ming Ni; Guo-Qiang Zhang; Hua-Wei Liu; Zhuo Zhang; Ji-Ying Chen; Yong-Gang Zhou; Yan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

3.  Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.

Authors:  Lijuan Wang; Yi Zhao; Jianfei Qian; Luhong Sun; Yong Lu; Haiyan Li; Yi Li; Jing Yang; Zhen Cai; Qing Yi
Journal:  Cancer       Date:  2012-08-22       Impact factor: 6.860

4.  TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells.

Authors:  Ellen J Beswick; Jameel R Johnson; Jamal I Saada; Martin Humen; Jenifer House; Sara Dann; Suimin Qiu; Allan R Brasier; Don W Powell; Victor E Reyes; Irina V Pinchuk
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

5.  Bacterial Lipopolysaccharides Induce Steroid Sulfatase Expression and Cell Migration through IL-6 Pathway in Human Prostate Cancer Cells.

Authors:  Hee-Jung Im; Na-Hee Park; Yeo-Jung Kwon; Sangyun Shin; Donghak Kim; Young-Jin Chun
Journal:  Biomol Ther (Seoul)       Date:  2012-11       Impact factor: 4.634

6.  Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.

Authors:  Kaiyuan Wang; Jian Wang; Feng Wei; Ning Zhao; Fan Yang; Xiubao Ren
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

7.  Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.

Authors:  Agm Mostofa; Allison Distler; Mark B Meads; Eva Sahakian; John J Powers; Alexandra Achille; David Noyes; Gabriela Wright; Bin Fang; Victoria Izumi; John Koomen; Rupal Rampakrishnan; Tuan P Nguyen; Gabriel De Avila; Ariosto S Silva; Praneeth Sudalagunta; Rafael Renatino Canevarolo; Maria D Coelho Siqueira Silva; Raghunandan Reddy Alugubelli; Hongyue A Dai; Amit Kulkarni; William S Dalton; Oliver A Hampton; Eric A Welsh; Jamie K Teer; Alexandre Tungesvik; Kenneth L Wright; Javier Pinilla-Ibarz; Eduardo M Sotomayor; Kenneth H Shain; Jason Brayer
Journal:  JCI Insight       Date:  2021-12-22

Review 8.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

9.  Combinations of TLR ligands: a promising approach in cancer immunotherapy.

Authors:  Saskia Stier; Claudia Maletzki; Ulrike Klier; Michael Linnebacher
Journal:  Clin Dev Immunol       Date:  2013-11-25

10.  Multiple Myeloma Index for Risk of Infection.

Authors:  Valkovic T; Gacic V; Nacinovic-Duletic A
Journal:  J Cancer       Date:  2018-06-04       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.